0 CHECKOUT

Skin And Soft Tissue Infections - Pipeline Review, H1 2015

  • ID: 3345032
  • June 2015
  • Region: Global
  • 137 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Allergan Plc
  • Cempra, Inc.
  • CrystalGenomics, Inc.
  • GlaxoSmithKline Plc
  • Motif Bio Plc
  • Phosphagenics Limited
  • MORE

This report provides comprehensive information on the therapeutic development for Skin And Soft Tissue Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Skin And Soft Tissue Infections and special features on late-stage and discontinued projects.

the report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from the proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by the team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Allergan Plc
  • Cempra, Inc.
  • CrystalGenomics, Inc.
  • GlaxoSmithKline Plc
  • Motif Bio Plc
  • Phosphagenics Limited
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Skin And Soft Tissue Infections Overview
Therapeutics Development
Pipeline Products for Skin And Soft Tissue Infections - Overview
Pipeline Products for Skin And Soft Tissue Infections - Comparative Analysis
Skin And Soft Tissue Infections - Therapeutics under Development by Companies
Skin And Soft Tissue Infections - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Skin And Soft Tissue Infections - Products under Development by Companies
Skin And Soft Tissue Infections - Companies Involved in Therapeutics Development
Allergan Plc
Atox Bio Inc.
Cempra, Inc.
CorMedix, Inc.
CrystalGenomics, Inc.
Debiopharm International S.A.
Dong-A Socio Group
GlaxoSmithKline Plc
Melinta Therapeutics, Inc
MicuRx Pharmaceuticals, Inc.
Motif Bio Plc
Nabriva Therapeutics AG
NovaDigm Therapeutics, Inc.
Phosphagenics Limited
Takeda Pharmaceutical Company Limited
Tetraphase Pharmaceuticals Inc.
The Medicines Company
Wockhardt Limited
Skin And Soft Tissue Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AB-103 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
acorafloxacin hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BC-7013 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ceftaroline fosamil - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CG-400549 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CRMD-004 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Debio-1450 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Debio-1452 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
delafloxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
eravacycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fusidic acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
gepotidacin mesylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
iclaprim mesylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IOG-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KBP-7072 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
lefamulin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MRX-I - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mul-1867 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NDV-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nu-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
oritavancin diphosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
radezolid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
siderocillin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Skin Infections - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit DHFR for Infectious Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tedizolid phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VAL-301 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
WCK-2349 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Skin And Soft Tissue Infections - Recent Pipeline Updates
Skin And Soft Tissue Infections - Dormant Projects
Skin And Soft Tissue Infections - Discontinued Products
Skin And Soft Tissue Infections - Product Development Milestones
Featured News & Press Releases
Sep 29, 2014: Atox Bio Awarded Contract Worth up to $24 Million for the Development of AB103 by the Biomedical Advanced Research and Development Authority
Aug 05, 2014: AB103 Granted Orphan Medicinal Product Designation in the European Union for the Treatment of Necrotizing Soft Tissue Infections
Aug 05, 2014: Cubist’s Once-daily SIVEXTRO (tedizolid phosphate) Available for Physician and Hospital Order in I.V. and Oral Formulations
Mar 31, 2014: FDA Advisory Committee Unanimously Recommends Approval of Cubist’s SIVEXTRO (Tedizolid Phosphate) as Treatment for Serious Skin Infections
Feb 27, 2014: Cubist Announces EMA Acceptance of Tedizolid Marketing Authorization Application for Review
Nov 20, 2012: Atox Bio Announces Positive Top-line Results In AB103 Necrotizing Soft Tissue Infections Phase IIa Trial
Sep 10, 2012: Atox Bio’s AB103 Receives FDA Fast Track Designation For Treatment Of Necrotizing Soft Tissue Infections
Oct 25, 2011: Atox Bio Receives Orphan Drug Designation For AB103 For Treatment Of Necrotizing Soft Tissue Infections
May 05, 2011: Furiex To Present Two Abstracts Featuring JNJ-Q2 At Joint Meeting Of ECCMID And ICC
Oct 15, 2010: Cempra To Present New Data On TAKSTA At Annual Meeting Of Infectious Diseases Society Of America
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Skin And Soft Tissue Infections, H1 2015
Number of Products under Development for Skin And Soft Tissue Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Comparative Analysis by Unknown Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Skin And Soft Tissue Infections - Pipeline by Allergan Plc, H1 2015
Skin And Soft Tissue Infections - Pipeline by Atox Bio Inc., H1 2015
Skin And Soft Tissue Infections - Pipeline by Cempra, Inc., H1 2015
Skin And Soft Tissue Infections - Pipeline by CorMedix, Inc., H1 2015
Skin And Soft Tissue Infections - Pipeline by CrystalGenomics, Inc., H1 2015
Skin And Soft Tissue Infections - Pipeline by Debiopharm International S.A., H1 2015
Skin And Soft Tissue Infections - Pipeline by Dong-A Socio Group, H1 2015
Skin And Soft Tissue Infections - Pipeline by GlaxoSmithKline Plc, H1 2015
Skin And Soft Tissue Infections - Pipeline by Melinta Therapeutics, Inc, H1 2015
Skin And Soft Tissue Infections - Pipeline by MicuRx Pharmaceuticals, Inc., H1 2015
Skin And Soft Tissue Infections - Pipeline by Motif Bio Plc, H1 2015
Skin And Soft Tissue Infections - Pipeline by Nabriva Therapeutics AG, H1 2015
Skin And Soft Tissue Infections - Pipeline by NovaDigm Therapeutics, Inc., H1 2015
Skin And Soft Tissue Infections - Pipeline by Phosphagenics Limited, H1 2015
Skin And Soft Tissue Infections - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015
Skin And Soft Tissue Infections - Pipeline by Tetraphase Pharmaceuticals Inc., H1 2015
Skin And Soft Tissue Infections - Pipeline by The Medicines Company, H1 2015
Skin And Soft Tissue Infections - Pipeline by Wockhardt Limited, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Skin And Soft Tissue Infections Therapeutics - Recent Pipeline Updates, H1 2015
Skin And Soft Tissue Infections - Dormant Projects, H1 2015
Skin And Soft Tissue Infections - Dormant Projects (Contd..1), H1 2015
Skin And Soft Tissue Infections - Discontinued Products, H1 2015

List of Figures
Number of Products under Development for Skin And Soft Tissue Infections, H1 2015
Number of Products under Development for Skin And Soft Tissue Infections - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Products, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Note: Product cover images may vary from those shown
3 of 4

Allergan Plc
Atox Bio Inc.
Cempra, Inc.
CorMedix, Inc.
CrystalGenomics, Inc.
Debiopharm International S.A.
Dong-A Socio Group
GlaxoSmithKline Plc
Melinta Therapeutics, Inc
MicuRx Pharmaceuticals, Inc.
Motif Bio Plc
Nabriva Therapeutics AG
NovaDigm Therapeutics, Inc.
Phosphagenics Limited
Takeda Pharmaceutical Company Limited
Tetraphase Pharmaceuticals Inc.
The Medicines Company
Wockhardt Limited

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PURCHASING OPTIONS

HAVE A QUESTION?

EMAIL US VIEW FAQs

RELATED PRODUCTS from Db

Our Clients

  • Genentech, Inc.
  • GlaxoSmithKline PLC
  • Maquet Getinge Group
  • Emergent BioSolutions, Inc.
  • Aicuris GmbH & Co.KG
  • Merck & Co., Inc.